U.S., Nov. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07253155) titled 'Probiotics Use and Preventing Gastrointestinal Symptoms in People Living With Overweight and Obesity.' on Sept. 23.
Brief Summary: Inflammatory bowel disease (IBD) affects over 6.8 million people worldwide, with current treatments often causing side effects and poor patient compliance. Dysbiosis of gut microbiota is a key factor, and while probiotics are considered safe and beneficial, conventional strains fail to function effectively during active inflammation due to high iron levels in the gut. Streptococcus thermophilus (FX856), unlike traditional probiotics, can thrive in this iron-rich environment, promoting mucosal healing. A ...